在PRISM研究中的Type2-Biologics中,预测严重的乙酸性喘早期和晚期肺功能改善的预测因素
Duong Duc Pham1, Ji-Hyang Lee1, Hyouk-Soo Kwon1
1Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.
Lung
|January 22, 2024
概括
预测肺功能改善的预测者在严重的酸性喘 (SEA) 中有所不同. 较低的FEV1基线和高的乙氨基预测了早期反应,而高的ACT得分预测了以后的生物治疗改善.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重的酸性喘 (SEA) 是一个具有挑战性的疾病.
- 在SEA中确定治疗反应的预测因素对于优化患者护理至关重要.
- 生物治疗 (BioT) 为SEA提供了新的治疗选择,但反应存在变化.
研究的目的:
- 在接受生物治疗的SEA患者中确定早期 (1个月) 和晚期 (6个月) 肺功能改善的预测因素.
- 了解影响严重酸性喘时对生物药物治疗反应的因素.
主要方法:
- 研究了一组由140名SEA成年患者组成的队列,这些患者接受了梅波利祖马布,杜皮卢马布或复利祖马布治疗.
- 肺功能,特别是1秒内强制呼气体积 (FEV1),在6个月内进行了评估.
- 使用后勤回归分析来确定预后因素与FEV1改善之间的关联.
主要成果:
- 在接受BioT治疗的SEA患者中,超过三分之一的患者在1个月内显示出早期和持续的FEV1改善.
- 低基线FEV1和高血中乙氨基酸细胞计数预测1个月后FEV1持续改善.
- 在1个月后没有反应的人中,39%的人在6个月后有所改善,高喘控制测试 (ACT) 得分是这种迟到反应的关键预测因素.
结论:
- 在接受生物药物治疗的SEA患者中,肺功能改善的预测因素因反应时间不同而有所不同.
- 早期治疗的成功与基线肺功能和氨酸细胞水平有关.
- 晚期治疗反应者通过更高的喘控制得分来确定.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
302
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
302
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
299
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
299
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:17Drugs Used in Lower Respiratory Disorders: Overview
445
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
445
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
01:26COPD: Management Using Bronchodilators and Corticosteroids
208
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
208